STAT Plus: Promising results for previously secret cancer drug data that ‘justified’ Gilead Sciences’ $21 billion acquisition
When Gilead Sciences announced its $21 billion acquisition of Immunomedics one week ago, Gilead executives said that clinical data on Immunomedics’ cancer drug Trodelvy — shared confidentially during negotiations — justified the high cost of the deal.
On Saturday, data from Trodelvy studies in bladder cancer and triple-negative breast cancer were presented publicly for the first time at the annual meeting of the European Society for Medical Oncology.